Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Phenylthiohydantoin
  • Prostatic Neoplasms, Castration-Resistant
  • Taxoids

abstract

  • In this heavily pretreated EAP population with progressive mCRPC, enzalutamide was well tolerated and the safety profile was consistent with that of the AFFIRM trial.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5024054

Digital Object Identifier (DOI)

  • 10.1002/pros.22965

PubMed ID

  • 25683285

Additional Document Info

start page

  • 836

end page

  • 44

volume

  • 75

number

  • 8